Research
Research grants
Development of a novel chick embryo model to discover and investigate therapeutics for uveal melanoma metastatic to the liver.
NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH (UK)
September 2023 - October 2027
Translational Safety Biomarker Pipeline: Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease (TransBioLine)
EUROPEAN COMMISSION
February 2019 - January 2025
Development of a multicell model of human liver
WANNAN MEDICAL COLLEGE (CHINA)🚩
January 2017 - December 2017
Biomarker analysis from BACE inhibitor project
JANSSEN PHARMACEUTICALS (BELGIUM)
November 2017 - March 2018
TransQST: Translational quantitative systems toxicology to improve the understanding of the safety of medicines
EUROPEAN COMMISSION
January 2017 - August 2022
To examine the potential preclinical value of mechanism-based biomarkers of DILI over more established and widely accepted clinical diagnostics related to liver histopathology. Development and qualification of the use of a combination of established and mechanism-based biomarkers (HMGB1(+Ac/-Ac); cytokeratin 18 or ccK18; Mir122) for DILI assay in preclinical studies (CDSS DILI Project)
MERCK & CO., INC. (USA)
February 2020 - February 2024
Identification of actionable drug targets in extra-hepatic Cholangiocarcinoma
AMMF THE CHOLANGIOCARCINOMA CHARITY(THE ALAN MOREMENT MEMORIAL FUND)(UK)
December 2017 - December 2018
Evaluation of Organoids and Systems Biology to develop Adverse Outcome Pathways of Gastrointestinal Toxicity (ITTP Studentship)
MEDICAL RESEARCH COUNCIL
October 2018 - September 2022
Determining the efficacy and safety of cancer chemotherapeutics for cholangiocarcinoma (CCA) using Human Precision Cut Tissue Slices (hPCTS).
NATIONAL CENTRE FOR THE REP, REF AND RED OF ANIMALS USED IN RESEARCH (NC3RS)
August 2021 - September 2023
Senior Technician at ULIV for TransBioLine
ELI LILLY AND COMPANY LTD (UK)
April 2022 - March 2024
Automated high-resolution microscope platform with robotics to study pharmacodynamics in 3D cell cultures
MEDICAL RESEARCH COUNCIL
November 2022 - March 2023
Bench Fees for Mohammed N. Bosakhar (201284267)
THE CULTURAL OFFICE OF THE EMBASSY OF THE STATE OF KUWAIT (UK)
January 2022 - January 2025
Senior Technician at ULIV for TransBioLine
PFIZER LTD (UK)
April 2022 - March 2024
Senior Technician at ULIV for TransBioLine
MERCK SHARP & DOHME LTD (UK)
April 2022 - March 2024
Preclinical evaluation of Nrf2 inhibition as a means to improve chemotherapeutic efficacy in patients with pancreatic cancer
PANCREATIC CANCER RESEARCH FUND (UK)
February 2016 - January 2020
Mechanistic investigation and risk:benefit analysis of the use of brusatol as a novel adjuvant for overcoming cisplatin resistance in bladder cancer
NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH (UK)
February 2016 - February 2018
Nanoparticle Interventions for Colorectal Cancer
CANCER RESEARCH UK (UK)
October 2016 - September 2021
Developing a collaborative resource for ChIP based analyses of cancer related transcriptional networks
CANCER RESEARCH UK (UK)
April 2012 - March 2013
Vacation Scholarship. The role of the Nrf2-keap 1 pathway in regulation of chemoresistance.
WELLCOME TRUST (UK)
July 2008 - August 2008
Regenerative Medicine Platform in Stem Cell Safety Science
MEDICAL RESEARCH COUNCIL
June 2013 - March 2018
Definition of the mechanisms that underlie the decrease in expression of the cytochrome P450s in primary hepatocytes.
BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL
June 2007 - December 2009
Manipulation of the physiological and toxicological phenotype of human hepatocytes by targeting cellular differentiation and de-differentiation
MEDICAL RESEARCH COUNCIL
October 2014 - September 2018
Investigation of Inflammatory Signalling during Drug-induced Hepatotoxicity Background
BRITISH TOXICOLOGY SOCIETY (UK)
October 2007 - September 2010
The chemical and molecular basis of the prevention of drug-induced liver injury by Nrf2.
WELLCOME TRUST (UK)
January 2007 - December 2009
Pharmacogenetic and functional analysis of novel GSTP1 polymorphism.
ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)
May 2005 - January 2007
Investigation of the role of Nrf2 in man
WELLCOME TRUST (UK)
October 2011 - May 2015
Mechanism and effect of Chinese antioxidant herbs on phase II drug-metabolizing enzymes.
ROYAL SOCIETY (CHARITABLE)
July 2005 - October 2005
Capacity building award in integrative mammalian biology
BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL
January 2007 - October 2015
Biomedical Vacation Scholarships
WELLCOME TRUST (UK)
July 2010 - August 2010
University of Liverpool Institutional Discipline Bridging.
MEDICAL RESEARCH COUNCIL
October 2003 - October 2006
Analysis of inter-individual variation in the inducibility of the antioxidant response by Nrf2: an important element in the defence against cancer.
NORTH WEST CANCER RESEARCH FUND
May 2005 - April 2006
Hepatocyte Phenotype Project: Phase II proposal
STEM CELLS FOR SAFER MEDICINES LTD (UK)
May 2011 - May 2014